nd conference institute for medicine and communication...
Post on 19-Oct-2020
1 Views
Preview:
TRANSCRIPT
Org
aniz
ed b
y IM
K In
stitu
te fo
r med
icin
e an
d co
mm
unic
atio
n Lt
d2nd Conferenceof the International MS Cognition Society
June 28-29, 2013University Hospital Zurich, Switzerlandwww.imk.ch/imscogs2013
Program
2
Zusa
mm
enfa
ssun
g Fa
chin
form
atio
n Be
tafe
ron.
Zusa
mm
ense
tzun
g: E
ine
Dur
chst
echf
lasc
he e
nthä
lt al
s W
irkst
off:
Inte
rfer
onum
bet
a-1b
AD
Nr
(8 M
io. I
U/m
l nac
h Re
kons
titut
ion)
Hilf
ssto
ffe:
Hum
anal
bum
in, M
anni
tol.
Indi
katio
nen:
Bei
Pat
ient
en m
it sc
hubf
örm
ig-r
emitt
iere
nder
Mul
tiple
r Sk
lero
se (
MS)
. Bei
sek
un-
där
chro
nisc
h-pr
ogre
dien
ter
MS
und
bei P
atie
nten
mit
eine
m e
rste
n kl
inisc
hen,
auf
MS
hinw
eise
nden
neu
rolo
gisc
hen
Erei
gnis.
Dos
ieru
ng/A
nwen
dung
: Erw
achs
ene
und
Kin
der
und
Juge
ndlic
he ü
ber
12 J
ahre
: 8 M
illio
nen
IU, a
ls In
jekt
ion
alle
zw
ei T
age
subk
utan
. K
ontr
aind
ikat
ione
n: Ü
bere
mpf
indl
ichk
eit
gege
n na
türli
ches
ode
r re
kom
bina
ntes
Int
erfe
ron
beta
ode
r H
uman
albu
min
; Sc
hwan
gers
chaf
t; sc
hwer
e de
pres
sive
Erkr
anku
ngen
und
/ode
r Su
izid
neig
ung
in d
er A
nam
nese
; Le
berin
suff
izie
nz;
nich
t ad
äqua
t ko
ntro
llier
te
Epile
psie
. Vor
sich
tsm
assn
ahm
en: V
orsic
ht b
ei P
atie
nten
mit
depr
essiv
en S
töru
ngen
ode
r K
ram
pfan
fälle
n in
Ana
mne
se; P
atie
nten
unt
er A
ntie
pile
ptik
a, m
it A
näm
ie, T
hrom
bozy
tope
nie,
Leu
kope
nie
oder
ges
tört
er S
child
drüs
enfu
nktio
n. V
or B
ehan
dlun
gsbe
ginn
und
in
rege
lmäs
sigen
Abs
tänd
en fo
lgen
de K
ontr
olle
n: v
ollst
ändi
ges B
lutb
ild, D
iffer
entia
lblu
tbild
, übl
iche
Lab
orw
erte
, GO
T, G
PT, G
amm
a-G
T. In
tera
ktio
nen:
Vor
sicht
bei
Ein
nahm
e vo
n Su
bsta
nzen
, der
en C
lear
ance
star
k vo
m Z
ytoc
hrom
-P45
0-Sy
stem
abh
ängt
. Sch
wan
gers
chaf
t/St
illze
it: F
raue
n im
geb
ärfä
hige
n A
lter s
ollte
n ge
eign
ete
Kon
traz
eptio
nsm
assn
ahm
en tr
effe
n. W
ähre
nd d
er S
tillz
eit e
ntw
eder
das
Stil
len
oder
die
Beh
andl
ung
mit
Beta
fero
n ab
brec
hen.
Une
rwün
scht
e W
irkun
gen:
Seh
r häu
fig: R
eakt
ione
n an
der
Inje
ktio
nsst
elle
, grip
pear
-tig
e Sy
mpt
ome.
Häu
fig: H
autn
ekro
sen.
Gel
egen
tlich
: Anä
mie
, Thr
ombo
zyto
peni
en, L
euko
peni
e, E
rhöh
unge
n de
r SG
OT-
, SG
PT-,
Gam
ma-
GT-
, Bili
rubi
n-, T
rigly
cerid
e-W
erte
; und
erh
öhte
r M
uske
ltonu
s, D
epre
ssio
n, a
rter
ielle
Hyp
erto
nie,
Übe
lkei
t, Er
brec
hen,
Haa
raus
fall,
U
rtik
aria
, Pru
ritus
, Exa
nthe
m u
nd M
yalg
ie. S
onst
ige
Hin
wei
se: L
ager
ung
unte
r 25°
C, n
icht
ein
frie
ren.
Hal
tbar
keit
des P
rodu
kts n
ach
Reko
nstit
utio
n bi
s zu
3 St
unde
n be
i 2-8
°C. V
erka
ufsk
ateg
orie
: B. W
eite
rfüh
rend
e In
form
atio
nen
entn
ehm
en S
ie b
itte
der F
achi
nfor
mat
ion
au
f w
ww
.swiss
med
icin
fo.c
h.
L.CH
.STH
.03.
2013
.011
7-D
E/FR
/IT1
Goo
din
et a
l. Su
rviv
al in
MS.
A r
ando
miz
ed c
ohor
t st
udy
21 y
ears
aft
er t
he s
tart
of
the
pivo
tal I
FNβ-
1b t
rial
. Neu
rolo
gy 2
012;
78:
131
5-13
22.
L.CH
.STH
.12.
2012
.009
1-D
E/FR
Bayer (Schweiz) AGGrubenstrasse 6, 8045 Zürich
Signifi kanter Überlebensvorteil Eine initiale Betaferon®-Behandlung resultiert in einer Risikoreduktion derMortalität um 47%, im Vergleich zur Placebo-Gruppe.1
Betaferon® – mit Familie in die Zukunft.
3
Contents
Welcome 5
General information 6
Accommodation 9
Travel information 10
Social program 12
Partner companies 13
Scientific program 14-21
Friday | 28.06.2013 14
Saturday | 29.06.2013 18
Adresses of invited speakers 23
Posters 25
Registration and hotel booking:
www.imk.ch/imscogs2013
2011-1
1-C
HE-
TYS
-109-d
Referenzen: 1. Kappos L et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007;6:431 – 441Gekürzte Fachinformation TYSABRI. Z: Eine Durchstechflasche enthält 300 mg/15 ml (20 mg/ml) Natalizumab. I: Monotherapie von schubförmig remittierend verlau-fender Multipler Sklerose bei Patienten mit hoher Krankheitsaktivität trotz Behandlung mit einem Interferon beta oder bei Patienten mit rasch fortschreitendem Verlauf. Bei Indikationsstellung bzw. vor Therapiebeginn das PML-Risiko berücksichtigen (siehe V). D: 300 mg alle 4 Wochen als intravenöse Infusion. Die Therapie mit TYSABRI muss von Spezialisten (Neurologen) in Zentren mit raschem Zugang zu MRI (Magnetresonanztomographie) eingeleitet und überwacht werden. Patienten sind in einem für TYSABRI vorgesehenen Monitoringprogramm aufzunehmen. KI: Überempfindlichkeit auf Natalizumab oder einen Hilfsstoff; Progressive Multifokale Leukoenzepha-lopathie (PML); erhöhtes Risiko für opportunistische Infektionen; Kombination mit Interferon beta oder Glatirameracetat; aktive Malignome; Personen unter 18 Jahren. V: Erhöhtes Risiko für die Entwicklung einer PML bei Vorliegen von folgenden unabhängigen Risikofaktoren: Vorhandensein von anti-JCV Antikörpern; immunsuppressive Behandlung vor der Therapie mit TYSABRI; Behandlungsdauer länger als 2 Jahre. Patienten mit allen drei Risikofaktoren tragen das höchste PML-Risiko. Für die Risiko-stratifizierung vor oder während der Behandlung sollte die Untersuchung auf anti-JCV-Antikörper erfolgen. Aufklärung des Patienten nach 2-jähriger Behandlungsdauer über das mit TYSABRI verbundene PML-Risiko notwendig; erhöhtes Risiko der Entwicklung eines IRIS (Immune Reconstitution Inflammatory Syndrome) bei Patienten mit PML; erhöhtes Risiko von opportunistischen Infektionen; Risiko von Überempfindlichkeitsreaktionen einschliesslich schwerer systemischer Reaktionen während oder kurz nach der Infusion; insbesondere bei den ersten Infusionen bzw. bei Anwendung nach kurzzeitiger Exposition und einer längeren Zeitdauer ohne Behandlung; nach einer früheren Behandlung mit Immunsuppressiva ausreichende Erholung des Immunstatus notwendig; Untersuchung auf Antikörper notwendig, falls Verschlechterung der Erkrankung oder infusionsbedingte Ereignisse. Vorsicht bei Beendigung der Therapie: pharmakodynamische Wirkung hält noch ca. 12 Wochen an. S: TYSABRI darf nicht in der Schwangerschaft verwendet werden, es sei denn, der klinische Befund macht dies erforderlich. Das Stillen sollte während der Behandlung mit TYSABRI beendet werden. UW: Kopfschmerzen, Erbrechen, Fieber, Abgeschlagenheit, Gelenkschmerzen, Harnwegsinfektionen, Nasopharyngitis, Urtikaria. Infusionsbedingte Reaktionen wie Schwindel, Übelkeit, Urtikaria, Rigor, Schüttelfrost, Flushing und Überempfindlichkeitsreaktionen (Siehe V). Infektionen einschliesslich PML und oppor-tunistische Infektionen. Antikörperbildung. Selten: Leberschädigung, erhöhte Leberenzyme. IA: Siehe unter KI. Liste B. Die vollständige Fachinformation ist unter www.swissmedicinfo.ch publiziert. Biogen Idec Switzerland AG, CH-6300 Zug. Stand der Information: August 2011.
Jetzt…
hoch- Wirksam1
BeI MS
… für Morgen
BIOG150 Inserat TYS_148x210+3mm_D_V01.indd 1 22.03.13 14:23
Welcom
e
5
Welcome from the president of the scientific committee
Dear colleagues
On behalf of the national and the executive committee, it is with great pleasure that we invite you to the 2nd Conference of the International MS Cognition Society (IMSCOGS) which will take place from June 28 to 29, 2013 at the University Hospital in Zurich, Switzerland. The upcoming event in Zurich will offer an excellent platform for discussing a topic which is highly relevant for patients’ quality of life and which is still underestimated by treating physicians. The International MS Cognition Society aims to bring together researchers and clinicians around the world who are engaged in the care of MS patients with a specific focus on cognition and other closely related symptoms such as fatigue, depression and anxiety. No effort was spared in order to organize an attractive and diverse program which undoubtedly will foster interesting debates and discussions. We are looking forward to welcoming you in Zurich in June 2013!
PD Iris-Katharina Penner, PhD
President of the committeeBasel, Switzerland
6
Gene
ral
General information
Date
Venue
Website
President IMSCOGS
Scientific committee
Congress secretariat
Friday, June 28 until Saturday, June 29, 2013
Universtity Hospital ZurichGrosser Hörsaal OST BGloriastrasse 29CH - 8091 ZürichWeb: www.usz.ch
www.imk.ch/imscogs2013
Prof. Bruno Brochet, MD; Bordeaux, F
National committee SwitzerlandPD Iris-Katharina Penner, PhD; Basel | Congress PresidentClaudio Gobbi, MD; LuganoProf. Ludwig Kappos, MD; BaselProf. Jürg Kesselring, MD; ValensPD Michael Linnebank, MD; ZurichProf. Roland Martin, MD; ZurichProf. Heinrich Mattle, MD; BernProf. Klaus Opwis, PhD; BaselProf. Renaud Du Pasquier, MD; Lausanne
Executive committeeProf. Maria Pia Amato, MD; Florence, I Prof. Bruno Brochet, MD; Bordeaux, F | President of the societyProf. Ralph Benedict, PhD; Buffalo, US Prof. John DeLuca, MD; West-Orange, US Prof. Sten Fredrikson, MD; Stockholm, SE Païvi Hämäläinen, PhD; Masku, FINProf. Hans-Peter Hartung, MD; Düsseldorf, D Prof. Lauren Krupp, MD; New York, US Prof. Dawn Langdon, PhD; London, UK Prof. Xavier Montalban, MD; Barcelona, E Prof. Alan Thompson, MD; London, UK
IMK Institute for medicine and communication LtdMünsterberg 1, CH-4001 BaselPhone: +41 61 271 35 51, Fax: +41 61 271 33 38E-mail: congress@imk.chwww.imk.ch
7
General
General information General information
Opening hoursCongress secretariat
Opening hoursindustrial exhibition
Credits
Registration
Congress fees
Cancellation fees
Confirmation ofparticipation
Friday, June 28, 2013 08:00-17:30 hSaturday, June 29, 2013 08:00-15:00 h
Friday, June 28, 2013 08:30-17:30 hSaturday, June 29, 2013 08:30-15:00 h
We applied for credits from following society:Swiss Neurological Society
Online via www.imk.ch/imscogs2013for your participation at the congress, your accomodation in Zurichand the social evening.
Registration fees include participation to scientific meetings, entrance to the exhibition, meeting materials, coffee & lunch breaks.On site registrations are possible at the IMK congress secretariat. Fol-lowing credit cards are accepted onsite: Mastercard, Visa, Visa Electron, EC, PostFinance and American Express.
IMK must be informed about cancellations in written form until May 31, 2013. We will be able to reimburse 50% of the congress fees. After May 31, 2013 no refunds will be made.
You will receive a confirmation of participation at the congress secretariat.
Early bird until May 31, 2013
Regular from June 1, 2013
Social evening
Physicians CHF 190.- CHF 240.- CHF 100.-
Assistant/Nurses/Student
CHF 130.- CHF 180.- CHF 60.-
8
Gene
ral
Technical information
The meeting room is equiped with a beamer and laptop. We kindly ask you to bring your presentation on a USB Stick or CD to the meeting room at the latest one hour prior to your session. Presentations with your own laptop are possible.
The official congress language is English.
Please consult the final program for the exact time of your presentation. Within the Free Communications-Session you will have 15 minutes for your presentation (12 minutes presentation, 3 minutes discussion). The authors are requested to prepare a power point presentation.
Posterboards in the format 100cm x 175cm (wide x height) will be at your disposal. Hang-up of the posters: Friday, June 28, 2013 from 08:00 h in the poster exhibition.
Friday, June 28, 2013, 13:30-15:00 h. The authors are requested to present their posters during this time.
The abstracts will be published in the journal „Multiple Sclerosis“.
Presentation
Language Free Communications
Poster exhibition
Posterviewing
Publication
9
General
Technical information
For participants we offer rooms in different hotels. Please consult our website www.imk.ch/imscogs2013 to book your accommodation. Please find below a selection of hotels, further hotels will follow on our website.
Accommodation
Clardige Hotel Zurich
Steinwiesstrasse 8-10 | 8032 Zurich-city center
The Claridge Zurich boutique hotel offers awell-tended environment with furniture ofhigh quality materials. In combination withthe antique design it is perfect for peoplelooking for something special.
Single room for single use from CHF 260.-Double room for double use from CHF 313.-
Sorell Hotel Zürichberg
Orellistrasse 21 | 8044 Zurich
The Sorell Hotel Zürichberg is a unique designhotel high above the city of Zurich. Enjoy the calmand relaxing atmosphere of the hotel, with itsnatural environment far away from the hustle andbustle of the city. You will be inspired by thefantastic views of Zurich, Lake Zurich and the Alps.
Double room for single use from CHF 250.-
Hotel Basilea
Zähringerstrasse 25 | 8001 Zurich
The modern Hotel Basilea is located just a5 minute walk away from Zurich’s main railwaystation, right in the heart of the historic old town.The rooms are modern and functional and offerfree Wi-Fi connections.
Single room for single use from CHF 165.-Double room for double use from CHF 235.-
10
Gene
ral
Flights to Zurich with SWISS
As official carrier to this conference Swiss International Air Lines offers you the best booking flexibility together with Swiss product and service quality, all at a significantly discounted price. As the national airline of Switzerland we offer event participants a reduction of up to 15% off regular fares. Your stay in Switzerland begins the moment you board one of our aircraft. Special congress fares are indicated with a "C" and make it possible for you to rebook flexibly or cancel if necessary. Reductions depend on the fare type, routing and availability and are valid on the full SWISS network for flights to Switzerland, including flights operated by one of our partner airlines with an LX flight number. These fares are bookable with immediate effect for the travel period 14 days before and after the event.To take advantage of this offer, book simply and conveniently on swiss.com via the link "www.swiss.com/event". The necessary event code is: 2517-2059-4854-7868.
Zurich is located at the heart of Europe and the center of Switzerland, making it easily accessible from all directions – whether you travel by train, car, or plane. The international Zurich Airport is situated in close proximity to Zurich and is considered one of the world’s best airports. Transfers Zurich Airport - Zurich City
TaxiThe journey from the airport to the city center is just around 20 minutes by taxi. The taxi ranks are located directly by the exits at the Arrival terminals 1 and 2. The trip by taxi from the airport to the center of Zürich costs around CHF 50 (EUR 35).
Hotel Shuttle BusThe city hotel shuttle bus CHECK-IN all-ways offers services every 30 minutes (6:30am - 2pm and 5pm - 11pm) or every 60 minutes (2pm - 5pm) from Zurich Airport to Zurich City. Furthermore many hotels near to the airport and in the city offer their own courtesy bus service. These buses depart from the area in front of the Arrival terminals 1 and 2.
TrainThe railway station at the Zurich Airport is located directly beneath the Airport Shopping area, just minutes away from Check-Ins 1-3 as well as Arrival Halls 1 and 2. Trains run every 10 minutes to and from the Zurich Main Station during peak traffic times (travel time 10 minutes).Online Timetable: www.sbb.ch
Travel information
11
General
Directions in Zurich Coming from Zurich Main Railway Station, tramways Nr. 6 (direction "Zoo") and Nr. 10 (direction "Zurich Airport") will bring you to the tram stop "ETH / Universitätsspital", which is right in front of the main entrance of the University Hospital Zurich. However, in order to get to the Grosser Hörsaal OST B, the best way to enter the building is by using the entrance at Gloriastrasse 29 (on the left side of the building). The nearest tramstop to this entrance is called "Platte" and can be reached with tramway Nr. 6 from Zurich Main Station.
A detailled plan of the University Hospital Zurich may be found on the congress website:www.imk.ch/imscogs2013 in the heading «Travel information».
Travel information
12
Gene
ral
Social program
Speakers dinner
Social evening
Address
Costs
The speakers dinner will be held on Thursday, June 27, 2013 at the restaurant “Oberer Mönchhof“.Only for invited guests.
The social evening will take place on Friday, June 28 2013 at the „Hotel Zürichberg“. The restaurant perfectly combines the secret of creative and contemporary culinary art, elegance in a relaxed atmosphere and a fantastic view of Lake Zurich and the city of Zurich. Hotel ZürichbergOrellistrasse 21CH-8044 Zürichwww.zuerichberg.ch
Costs for physicians: CHF 100.-Costs for students, assistants and nurses: CHF 60.-
13
General
Social program Partner companies
We would like to thank the following companies for supporting the 2nd Conference ofthe International MS Cognition Society as a sponsor (updated in May 2013):
Premium Partner 2013
Partner 2013
Frid
ay
14
Daily overview Friday | 28.06.2013
Plenary Room Poster exhibition Industrial exhibition
09:00 - 09:15 Welcome
09:15 - 09:30 Neuroinflammationand
Neurodegeneration09:30 - 09:45
09:45 - 10:45 Free Communications
10:45 - 11:15 Coffee break
11:15 - 11:30 BICAMS,update
on validation11:30 - 11:45
11:45 - 12:30 Free Communications
12:30 - 13:30 Lunch
13:30 - 15:00 Guided Poster session
15:00 - 15:30 Coffee break
15:30 - 15:45 Utility of neuro-psychological testing in
children with MS15:45 - 16:00
16:00 - 16:45 Free Communications
16:45 - 17:30 Welcome reception
from 19:00 Social dinner
Main sessions Abstracts General informations Breaks
15
16
16
16
16
17
15
15
Friday
15
Friday | 28.06.2013
09:00-09:15
09:15-10:45
09:15-09:45
09:45-10:45
09:45-10:00
10:00-10:15
10:15-10:30
10:30-10:45
10:45-11:15
Welcome by the congress presidentPD Iris-Katharina Penner, PhD; Basel, CH Session IChairs: Prof. Bruno Brochet, MD; Bordeaux, F &Prof. Roland Martin, MD; Zurich, CH
Neuroinflammation and Neurodegeneration in relation to cognitionProf. Jeroen Geurts, PhD; Amsterdam, NL
unrestricted grant
Free communications
Callosal atrophy in multiple sclerosis is related to cognitive speedG. Bergendal, J. Martola, L. Stawiarz, M. Kristoffersen-Wiberg,S. Fredrikson, O. Almkvist; Stockholm, SE
It is all about speed: information processing speed and white matter integrity changes in MSJ. Burggraaff, H.H. Hulst, J.J.G. Geurts, M.M. Schoonheim, F. Barkhof, B.M.J. Uitdehaag, Ch. Polman; Amsterdam, NL
The impact of cortical thinning on executive dysfunction in MS patientsO. Geisseler, T. Pflugshaupt, L. Bezzola, K. Reuter, P. Brugger,B. Schuknecht, M. Linnebank; Zurich, CH, Lucerne, CH
The relationship between cognitive impairment and APOE genotype in a multiple sclerosis cohortP. Ioannidis, E. Aretouli, E. Konstantinopoulou, R. Lagoudaki, N. Grigoriadis, D. Karacostas; Thessaloniki, GR
Coffee break
Frid
ay
16
Friday | 28.06.2013
11:15-12:30
11:15-11:45
11:45-12:30
11:45-12:00
12:00-12:15
12:15-12:30
12:30-13:30
13:30-15:00
15:00-15:30
15:30-16:45
15:30-16:00
Session IIChairs: Prof. Xavier Montalban, MD; Barcelona,E &Prof. John DeLuca, MD; West-Orange, USA
BICAMS Update on validationProf. Ralph Benedict, PhD; Buffalo, USA
Free communications
Does the Brief International Cognitive Assessment for MS (BICAMS) catch the cognitive problems of a sample of well-educated recently diagnosed MS patients in Oslo?G.O. Nygaard, H.F. Harbo, E.G. Celius, N.I. Landrø; Oslo, NO
Reliable change indices for the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)S.Ó Donnchadha, T. Burke, J. Bramham, M.C. O’Brien, R. Reilly, H. Kiiski, R. Whelan, R. Lonergan, K. Kinsella, O. Kenny, S. Kelly, C. McGuigan, M. Hutchinson, N. Tubridy; Dublin, IR; Burlington; US
Parametric assessment of information processing capacity at different stages of Multiple Sclerosis (MS)P. Bublak, M. Schwab, R. Deppe, J. Faiss, M. Fischer, F. Hoffmann, A. Kunkel,P. Redel, E. Stadler,M. Sailer, K. Voigt, U.K. Zettl, W. Köhler; Jena, DE;Halle, DE; Teupitz, DE; Wermsdorf, DE; München, DE; Magdeburg, DE;Rostock, DE
Lunch
Guided Postersession in room “Kurszimmer OSTB“Chairs: PD Iris-Katharina Penner, PhD; BaselClaudio Gobbi, MD; LuganoPD Michael Linnebank, MD; Zurich
Coffee break
Session IIIChairs: Prof. Dawn Langdon, PhD; London, UK &Prof. Ralph Benedict, PhD; Buffalo, US
Utility of neuropsychological testing in children with MS Prof. Maria Pia Amato, MD; Florence, IT
Friday
17
Friday | 28.06.2013 Friday | 28.06.2013
16:00-16:45
16:00-16:15
16:15-16:30
16:30-16:45
16:45-17:30
From 19:00
Free communications
Longitudinal Evaluation of Cognitive Impairment in Pediatric MSL. Charvet, D. Serafin, K. Vazquez, J. Ackerson, E. Braaten, T. Brown, E. O’Donnell, J. Parrish, T. Preston, M. Zaccariello, A. Belman, C. Casper, T. Chitnis, M. Gorman, L. Julian, J. Ness, M. Patterson, M. Rodriguez, E. Waubant, B. Weinstock-Guttman, A. Yeh, R. Benedict, L. Krupp; Stony Brook, US; Tuscaloosa, US; Buffalo, US; Boston, US; Rochester, US; Salt Lake City, US; San Francisco, US; Toronto, CAHow accurate are self-reports of executive functioning in
Multiple Sclerosis?K. van der Hiele, N.G.A Kamminga, R.P. Ruimschotel, H.A.M. Middelkoop, L.H. Visser; Leiden, NL; Maassluis, NL; Rotterdam, NL; Tilburg, NL
6 years follow-up of attentional and cognitive functions in early relapsing-remitting multiple sclerosis (RRMS) patientsH. Schreiber, M. Lang, A. Fuchs, C. Kauderer, T. Fischer, M. Freidel, W. Hofmann, W. Elias, G. Reifschneider, S. Ries, B. Bühler, I. Uttner,S. Schlegel, C. Ring, I.K. Penner, A. Bergmann; Ulm, DE; Mutlangen, DE; Günzburg, DE; Offenbach, DE; Kaltenkirchen, DE; Aschaffenburg, DE; Hamburg, DE; Erbach, DE; Mannheim, DE; Ulm, DE; Neuburg, DE; Basel, CH
Welcome reception
Social evening at the Restaurant Zürichberg
Hotel ZürichbergOrellistrasse 21CH-8044 Zürichwww.zuerichberg.ch
Satu
rday
18
Daily overview Saturday | 29.06.2013
Plenary Room Poster exhibition Industrial exhibition
09:00 - 09:15 Optical coherence tomography-first data on
cognition09:15 - 09:30
09:30 - 10:45 Free Communications
10:45 - 11:15 Coffee break
11:15 - 11:30 Effects of non-pharmacological
approaches on cognitive functions11:30 - 11:45
11:45 - 12:30 Free Communications
12:30 - 13:30 Lunch
13:30 - 13:45 Effects of pharmacotherapy on cognitive functions13:45 - 14:00
14:00 - 14:30 Free Communications
14:30 - 15:30 Discussion
15:30 - 16:15 General AssemblyIMSCOGS
21
21
21
21
19
19
20
20
Main sessions Abstracts General informations Breaks
Saturday
19
Saturday | 29.06.2013
09:00-10:45
09:00-09:30
09:30-10:45
09:30-09:45
09:45-10:00
10:00-10:15
10:15-10:30
10:30-10:45
10:45-11:15
Session IVChairs: Prof. Lauren Krupp, MD; New York, USA &Prof. Maria Pia Amato, MD; Florence, IT
Optical coherence tomography-first data on cognition Prof. Paul Friedemann, MD; Berlin, D
unrestricted grant
Free communications
Prevalence and pattern of cognitive dysfunction in Indian patients with multiple sclerosisP. Agarwal, S. Johri, S.P. Gorthi, Y.S. Sirohi, N. Yaddanapudi; New Dehli, IN; Chandigarh, IN
Is visual function testing influenced by cognitive performance in multiple sclerosis?L. Wieder, L.M. Pech, G. Gäde, H. Zimmermann, J. Bellmann-Strobl, F. Paul, A.U. Brandt; Berlin, DE
Neuroimaging and Cognition using Near Infrared Spectroscopy in Multiple SclerosisJ. Stojanovic, G. Wylie, G.T. Voelbel, J. DeLuca; West Orange, US
Correlation of cerebral magnetic resonance elastography with cognitive performance in patients with multiple sclerosisE. Wuerfel, A. Brandt, K. Schregel, F. Paul, I. Sack, J. Wuerfel; Goettingen, DE; Berlin, DE; Luebeck, DE
Detection of cognitive impairment in MS based onan EEG P300 paradigmJ. Van Schependom, M.B. D’hooghe, M. D’hooge, K. Cleynhens, J. De Keyser, G. Nagels; Brussel, BE; Melsbroek, BE
Coffee break
Satu
rday
20
Saturday | 29.06.2013
Session VChairs: Prof. Sten Fredrikson, MD; Stockholm,SE & Prof. Herbert Schreiber, MD; Ulm, D
Effects of non-pharmacological approaches on cognitive functionsProf. John DeLuca, MD; West-Orange, USA
Free communications
Case-based approach to evaluate the efficacy of working memory training in juvenile Multiple SclerosisM. Hubacher, P. Weber, M. Stoecklin, K. Specht, L. Kappos, K. Opwis, I.K. Penner; Basel, CH; Bergen,
Long-term effects of cognitive rehabilitation in multiple sclerosis: 12-month follow-upB. Topcular, D. Yandim-Kuscu, I. Guclu, A. Altinkaya, D Kirbas,G Akman-Demir; Istanbul, TR
Personalized on-line (computer-based) cognitive training (CogniFit) for patients with MSA. Miller, E. Shatil; Haifa, IR; Yoqneam Ilit, IR
Lunch
11:15-12:30
11:15-11:45
11:45-12:30
11:45-12:00
12:00-12:15
12:15-12:30
12:30-13:30
Saturday
21
Saturday | 29.06.2013 Saturday | 29.06.2013
Session VIChairs: Prof. Alan Thompson, MD; London, UK &PD Iris-Katharina, PhD; Basel, CH
Effects of pharmacotherapy on cognitive functionsProf. Ludwig Kappos, MD; Basel, CH
Free communications
Impact of Natalizumab treatment on attention, mood and fatigue in relapsing-remitting MSA. Kunkel, J.H. Faiss, W. Köhler, M. Fischer; Teupitz, DE; Wermsdorf, DE
Repetitive transcranial magnetic stimulation improves working memory and induces changes in brain activity of Multiple Sclerosis patientsT. Goldschmidt, H.E. Hulst, S. De Wit, Y.D. van der Werf, O.A. van den Heuvel, F. Barkhof, C. Polman, M.A. Nitsche, J.J.G. Geurts; Amsterdam, NL; Goettingen, DE
Discussion and closing remarks
General assembly IMSCOGS
13:30-14:30
13:30-14:00
14:00-14:30
14:00-14:15
14:15-14:30
14:30-15:30
15:30-16:15
Promoting partners and partnership in hea lthcare
Institute for medicine and communication Ltd | Münsterberg 1 CH-4001 Basel | Phone +41 61 271 35 51 | Fax +41 61 271 33 38 | mail@imk.ch
Conference organizationAdministrative managementCommunications
IMIMWM Inserat A5_15.indd 1 23.05.13 14:13
Addresses
23
Adresses of invited speakers and committee
Page Page
6,1619
6,1617
6,15
6,1619,20
6,2025
19
AProf. Maria Pia Amato, MDUniversity of FlorenceDepartment of NeurologyViale Morgagni 85IT-50134, Florence
BProf. Ralph Benedict, PhDSUNY Buffalo School of Medicine100 High StreetUS-NY 14203 Buffalo
Prof. Bruno Brochet, MDUniversité Bordeaux-SegalenService de NeurologieF-33076 Bordeaux
DProf. John DeLuca, MDKessler Foundation1199 Pleasant Valley WayUS-NJ 07052 West Orange
FProf. Sten Fredrikson, MDKarolinska InstitutetR54, Karolinska University Hospital HuddingeSE-14186 Stockholm
Prof. Paul Friedemann, MDNeuroCure Clinical Research CenterCharitéplatzD-10117 Berlin
GProf. Jeroen Geurts, MDVrije University Medical CenterDepartment of Anatomy andNeurosciencesVan der Boechorststraat 7NL-1081 BT Amsterdamt
Claudio Gobbi, MDOspedale Civico, NeurologiaVia Tesserete 46CH-6900 Lugano
HProf. Hans-Peter Hartung, MDNeurologische KlinikHeinrich-Heine UniversitätMoorenstrasse 5D-40225 Düsseldorf
KProf. Ludwig Kappos, MDUniversity Hospital BaselNeurologyPetersgraben 4CH-4031 Basel
Prof. Jürg Kesselring, MDKlink Valens, Neurologieund NeurorehabilitationCH-7317 Valens
Prof. Lauren Krupp, MDStony Brook University Medical Center179 N Belle Mead RdUS-NY 11794-8121 New York
15,21
6
6
6,2021
6
6,1719
Addr
esse
s
24
Adresses of invited speakers and committee
Page Page
6,16
6,15
6,15
6
6,16
6,20
LProf. Dawn Langdon, PhDRoyal Holloway University of LondonEgham HillUK-Egham Surrey TW20 0EX London
PD Michael Linnebank, MDUniversitätsSpital ZürichKlinik für NeurologieFrauenklinikstasse 26CH-8091 Zurich
MProf. Roland Martin, MDUniversitätsSpital ZürichKlinik für NeurologieCH-8091 Zurich
Prof. Heinrich Mattle, MDInselspital BernNeurologisch-neurochirurgischePoliklinikCH-3010 Bern
Prof. Xavier Montalban, MD, PhDUnitat de Ressonància MagnèticaHospital Vall d’HebronPasseig Vall d’Hebron 119-129ES-08035 Barcelona
OProf. Klaus Opwis, PhDUniversität BaselInstitut für PsychologieCH-4055 Basel
PProf. Renaud Du Pasquier, MDCHUVNeurologie BH-1046, rue du BugnonCH-1011 Lausanne
PD Iris-Katharina Penner, PhDUniversity of BaselDepartment of Cognitive PsychologyMissionsstrasse 60/62CH-4055 Basel
SProf. Herbert Schreiber, MDNeurologische Praxisgemeinschaft UlmPfauengasse 8D-89073 Ulm
TProf. Alan Thompson, MDUCL Institute of NeurologyDepartment of Brain Repairand Rehabilitation8-11 Queen SquareUK-WC1N 3B London
6
6,1517
17,20
6,21
25
Posters
Posters
A lexical access deficit in Clinical Isolated Syndrome: correlation with brain MRI parametersH. Joly, M. Cohen, C. Lebrun; Nice (FR)
A possible influence of fatigue in the risk of work accidents in a sample of MS patientsC. Incerti, O. Argento, G. Magistrale, C. Caltagirone, G. Di Battista, E. Ferraro, U. Nocentini, V. Pisani; Rome (IT)
BRBN-T validation: Adapting the SRT and WLG tests to the Portuguese populationM. R. Neves, A.M. Passos, A. Ferreira, C. Sousa, M.J. Sá; Lisboa (PT), Porto (PT)
Cerebellum and cognition in multiple sclerosisB. Brochet, I. Lacoste, J. Charré-Morin, M. Deloire; Bordeaux (FR)
Cognitive changes during and after MS relapses - 6 months follow-upL. Vahter, L. Bachmann, T. Saarup, K. Rohulaid, K. Kannel, A. Reitsnik, U. Sorro, K. Gross-Paju; Tallinn (EE)
Cognitive Dysfunction Predicts Negative Work Events and Accommodations in Multiple SclerosisN.A. Emmert, J.D. Rodgers, R. Kininger, B. Weinstock-Guttman, R.H.B. Benedict; Buffalo (US)
Cognitive function in Turkish patients with relapsing remitting multiple sclerosisZ. Gedik, E. Idiman, S. Ozakbas; Izmir (TR)
Cognitive functioning in Multiple Sclerosis: the relationship with radial diffusivityR. Magalhães, L. Gomes, J. Alves, L. Maia, F. Palavra, J.G. Gonçalves, O.F. Gonçalves, A. Sampaio; Brage (PT), Coimbra (PT)
Computer-based assessment of memory and selective attention in MS patientsG. Adler, M. Bektas, N. Baumgart, Y. Lembach; Mannheim (DE)
Correlations between auditory consonant trigram test, paced auditory serial addition test health-related quality of life during and after treatment of relapses in patients with clinically isolated syndromeOzakbas, Piri Cinar, Ozturk, Gurkan, Idiman; Izmir (TR)
P01
P02
P03
P04
P05
P06
P07
P08
P09
P10
26
Post
ers
Posters
Diffustion tensor imaging and cognitive impairment in early relapsing-remitting multiple sclerosisS. Planel, R. Anxionnat, M. Debouverie, C. Latarche, G. Hossu, E. Micard, E. Morele, L. Rivail-Eloy, G. Lesanne, M. Domingo, A.L. Derelle, C. Barbier, E. Schmitt, M. Braun, S. Bracard;
Episodic short-term memory deficits in MS subtypesG. Adler, M. Bektas, N. Baumgart, Y. Lembach; Mannheim (DE)
Fatigue as the best predictor variable of self-rated disability in a sample of MS patientsG. Magistrale, R. Medori, D. Cadavid, O. Argento, C. Incerti, V. Pisani, C. Caltagirone, U. Nocentini; Rome (IT), Cambridge (US)
Fatigue is associated with radial diffusivity in patients with early stages of Multiple SclerosisL.R. Gomes, R. Magalhães, M. Parreira, L. Maia F. Palavra, G. Gonçalves, A. Sampaio, J.J. Cerqueira, O.F. Gonçalves; Braga (PT), Coimbra (PT)
fMRI during PASAT and PVSAT in healthy volunteers and patients with mild and moderate multiple sclerosisJ. Gielen, J. Van Schependom, W. Van Hecke, P. M. Parizel, G Nagels; Brussel (BE), Leuven (BE)
Impact of depression and fatigue on cognitive functions in multiple sclerosisV. Ignatova, Ts. Stoyanova, L. Todorova, L. Haralanov; Sofia (BG
Interest of moral/conventional judgment task in multiple sclerosis (MS) patientsN. Ehrle, A. Potet, A. Hody, M.P. Chaunu, A. Tourbah, S. Bakchine; Reims (FR)
Is the decrease of the qualitative performance at the end of attentional tests due to fatigue in multiple sclerosis patients?N. Moyano, G. Delrue, S. Genon, E. Jimenez, L. Denis, E. Hody, S. Adam, D. Guillaume; Fraiture-en-Condroz (BE), Liège (BE)
Modulation of alertness by sustained cognitive demand in MS as surrogate measure of fatigue and fatigabilityM. Neumann, D. Claros-Salinas, R. Gütler R. Ulrich, A. Sterr, C. Dettmers; Konstanz (DE), Tübingen (DE), Surrey (UK)
P11
P12
P13
P14
P15
P16
P17
P18
P19
27
Posters
Posters
Normative data for two parallel Italian Versions of CVLT-IIO. Argento, P. Vanzo, V. Pisani, G. Magistrale, C. Caltagirone, U. Nocentini; Rome (IT)
One-year cognitive follow-up of patients with clinically isolated syndromeM. López-Góngora, A. Martínez-Domeno, A. Escartin-Siquier; Barcelona (ES)
Pattern of cognitive impairment and related factors in clinically isolated syndromeOzakbas, Piri Cinar, Gurkan, Ozturk, Idiman; Izmir (TR)
Pupillometry indicates increased cognitive effort in response to easy cognitive taks in newly diagnosed MS patientsS.A. de Rodez Benavent, G.O. Nygaard, S. Tønnesen, E.G. Celius, N.I. Landrø, B. Laeng; Oslo (NO)
Social cognition in multiple sclerosis patientsC. Dulau, H. Diaz, A. Prouteau, M. Deloire, J. Charré-Morin, A. Saubusse, B. Brochet; Bordeaux (FR)
Spasticity perception in MS is not influenced by other concomitant symptoms like sleep, fatigue, and emotional or cognitive disordersA. Gil, C. González, S. Peralta, B. Guiu, M. Gil, E. Lacasa, L. Brieva; Lleida (ES)
The recently unemployed: Who are they and what is their disease, cognitive, and psychological profile?L.B. Strober, N. Chiaravalloti, J. DeLuca; West Orange (US)
Theory of Mind deficits in patients with Multiple Sclerosis – A separate entity of socio-cognitive impairment?D. Zwahlen, S. Schaub, Ö. Yaldizli, K. Opwis, J.M. Annoni, L. Kappos, I.K. Penner; Basel (CH), Fribourg (CH)
Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): UK normative dataA.J. Orchard, G. Giavanoni, D.W. Langdon; London (UK)
P20
P21
P22
P23
P24
P25
P26
P27
P28
Your partner in rare diseasesand multiple sclerosis
Fighting complex diseases with groundbreaking therapies.
Visit www.genzyme.com
genzyme_anzeige_A5_2012-08-13_v03_kh.indd 1 17.08.12 14:12
top related